Compare Pure Storage (P) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pure Storage vs Spyre Therapeutics Inc. Common Stock — how do they compare? Pure Storage trades at $137 (market cap $52.31B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Pure Storage is far larger — about 7× Spyre Therapeutics Inc. Common Stock's market cap, and Pure Storage is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Pure Storage for 4 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| P | SYRE | |
|---|---|---|
Market Cap | $52.31B | $7.52B |
Volume | 3,373,937 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $156.97 | $108.92 |
52-Week Low | $56.99 | $22.18 |
Typical Hold Time | 4 Days | 0 Days |
Enterprise Value | $51.52B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Everpure (P) trades at $156.97, up 1.07% today, near its 52-week high. The stock shows strong momentum with a bullish technical signal, supported by three consecutive quarterly earnings beats. Revenue grew from $3.17B in 2025 to $4.3B in 2026, with net income more than doubling. Recent news highlights a 147% six-month surge driven by AI-driven growth targets and positive investor sentiment.
Outlook remains optimistic due to robust earnings performance and AI expansion plans, but high valuation multiples (P/E 215) and overbought technical indicators pose risks. Analyst consensus is strongly bullish with a $141.47 price target, though insider selling and competitive pressures warrant caution for new investments.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Pure Storage
Pure Storage develops enterprise data storage and data management systems, primarily using all-flash technology. Its platform supports cloud, AI, analytics, and mission-critical application workloads.
Read more on P →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
